





LMKaplan0@gmail.com

# The Pathophysiology of Recurrent Weight Gain After MBS

Lee M. Kaplan, MD, PhD

Professor of Medicine and Chief, Section of Obesity Medicine Director, Dartmouth Weight and Wellness Center Geisel School of Medicine at Dartmouth

LMKaplan0@gmail.com

3 September 2024



Fernando Botero, 1932-2023

IFSO 2024 • Melbourne, Victoria, Australia

#### **Disclosures**

I am currently or have recently been a paid consultant to the following companies and organizations:

Altimmune Kallyope

Amgen Eli Lilly & Company

AstraZeneca Neurogastrx

Bain Capital Novo Nordisk

Boehringer Ingelheim Optum Health

Cytoki Perspectum

Ethicon Pfizer

Gelesis Sidekick Health

Gilead Sciences Skye Bioscience


Glyscend twenty30.health

Intellihealth Xeno Biosciences

Johnson & Johnson Zealand




# In obesity, the target fat mass is dysregulated (elevated) from environmental influences on biologically susceptible individuals





# **Effective** obesity treatments normalize fat mass regulation leading to decreased weight without activating metabolic adaptation






# Physiological weight loss is associated with blunting of metabolic adaptation

- Vehicle (placebo)
- -- Semaglutide, 9.7 nmol/kg/day
- -- Calorie restricted, weight-matched to semaglutide group

# Body weight 45 40 35 0 2 4 6 8 10 Time (days)

#### **Energy expenditure**





# RYGB effects are opposite to those of restrictive dieting


	Calorie restriction (non-physiological)	Metabolic surgery (physiological)
Energy expenditure	•	<b>^</b>
Appetite	<b>^</b>	<b>4</b>
Hunger	<b>^</b>	<b>4</b>
Satiety	•	<b>^</b>
Reward-based eating	<b>^</b>	<b>\</b>
Stress response	<b>^</b>	<b>\</b>
Gut peptides		
Ghrelin	<b>^</b>	<b>\</b>
GLP-1, PYY, CCK, amylin	•	<b>^</b>



- Promotion of non-physiological weight loss
  - Restrictive dieting



## Bariatric surgery: defense of a decreased body fat mass



#### Step 1:

- Obese, sham-operated controls (350 gm)
- **Thin**, chow-fed, unoperated (225 gm)
- Thin, underfed to match VSG weight (275 gm)
- Thin, underwent **VSG** (275 gm)

#### Step 2:

Calorie restrict to lose 30% body weight


#### Step 3:

Let them eat what they want




#### Effect of calorie restriction beyond physiological weight loss

STEP 1 Trial
Subjects without Diabetes
Drug Alone



STEP 3 Trial
Subjects without Diabetes
Drug Plus Calorie Reduction






- Promotion of non-physiological weight loss
  - Restrictive dieting
- Progression of disease



## Most recurrent weight gain is NOT from surgical or patient failure

#### **Long-term Progression of Obesity**




Time (years)



- Promotion of non-physiological weight loss
  - Restrictive dieting
- Progression of disease
- Environmental factors
  - Continued exposure to obesogenic environment
  - Environmental toxins
  - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
  - Obesogenic diet
  - Obesogenic medications



#### **Environmental influences raise the defended fat mass**





- Promotion of non-physiological weight loss
  - Restrictive dieting
- Progression of disease
- Environmental factors
  - Continued exposure to obesogenic environment
  - Environmental toxins
  - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
  - Obesogenic diet
  - Obesogenic medications
- Biological factors
  - Genetic predisposition?




## Medical therapy for suboptimal weight loss or recurrent weight regain

If surgery worked mechanically (restriction or malabsorption) ...

... combination with medications would be additive at most

Since surgery works physiologically ...

... complementary mechanisms allow for synergy






## Postoperative pharmacotherapy augments surgical weight loss

#### **GRAVITAS Study**

Liraglutide 1.8 mg vs. Placebo after Gastric Bypass
Patients with Type 2 Diabetes






26

## Liraglutide 3.0 mg augments weight loss after metabolic surgery

#### **BARI-OPTIMISE Trial**

Subjects with suboptimal (<20%) initial weight loss after metabolic surgery

Liraglutide 3.0 mg/day vs. placebo (N=70)





## Potential means of addressing recurrent weight gain

#### Cause of weight gain

**Potential solution** 

Promotion of non-physiological weight loss (purposeful calorie restriction beyond what surgery naturally provides)

Avoid recommending purposeful calorie reduction – let the surgery do its job!

Progression of disease

Add an additional therapeutic mechanism

- Start or add an anti-obesity medication
- Convert to a different MBS operation
- Add a complementary endoscopic treatment

**Environmental factors** 

Address the environmental factors or add an additional therapeutic mechanism

Surgical complication

Correct the surgical anatomy

Intrinsic biological or genetic factors

Add an additional therapeutic mechanism









LMKaplan0@gmail.com

# The Pathophysiology of Recurrent Weight Gain After MBS

Lee M. Kaplan, MD, PhD

Professor of Medicine and Chief, Section of Obesity Medicine Director, Dartmouth Weight and Wellness Center Geisel School of Medicine at Dartmouth

LMKaplan0@gmail.com

3 September 2024



Fernando Botero, 1932-2023

IFSO 2024 • Melbourne, Victoria, Australia